Home > Press Releases > Opioid Use Disorder (OUD) Market

Opioid Use Disorder (OUD) Market Anticipated to Reach ~USD 12 Billion by 2035

Report Code: HC-71405  |  Published in: Oct 2025, By MarketGenics  |  Number of pages: 283

An extensive study of propelling opportunities in, Opioid Use Disorder (OUD) Market Size, Share & Trends Analysis Report by Product Type (Neurovascular Stents, Embolic Coils, Neurothrombectomy Devices, Access Devices, Embolic Protection Devices, Neurovascular Balloon Catheters, Others), Procedure Type, Technology, Material Type, Indication/Disease Type, Patient Demographics, Deployment Method, Treatment Approach, End-users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035A comprehensive report of growing market landscapes in the opioid use disorder (OUD) sector uncovering key growth drivers including niche market leadership, technology-enabled distribution, and increasing consumer needs supporting opioid use disorder (OUD) potential to scale globally.

Global Opioid Use Disorder (OUD) Market Forecast 2035:

According to the report, the opioid use disorder (OUD) market is anticipated to grow from USD 4.2 Billion in 2025 to USD 11.8 Billion in 2035 at a CAGR of 10.9% during the forecast. The opioid use disorder (OUD) market is growing rapidly due to increased incidences of opioid addiction worldwide and increasing funding for integrated care models. Innovations are happening in telemedicine and remote monitoring in North America and Europe due to work being done by private companies and technology vendors. There are also VR-based clinician training programs made available to improve workforce capacities and increase treatment delivery.

Additionally, AI-powered platforms are being utilized for treatment plans, operationalized as scalable care solutions that offer personalized treatment options as the demand grows in developed and emerging markets. Trend transitions to Client-based care, called in-home care management, is also a catalyst for the growth of this market, as well as with the COVID-19 pandemic and recent changes in healthcare policies for remote care. There is significant investment in cybersecurity for connected treatment devices to keep data secure for sensitive patient information.

“Key Driver, Restraint, and Growth Opportunity Defining the Global Opioid Use Disorder (OUD) Market”

The global market for opioid use disorder (OUD) is on the rise due to the increasing rates of opioid addiction and demand for more accessible and patient-centered treatment options. Advances in telemedicine, digital health platforms, and AI-enabled digital monitoring are increasing the personalization of care and the possibility of continuous care and monitoring from the comfort of the patient’s home, which will also continue to encourage growth in the market. Increased awareness campaigns and government-level initiatives are also leading to increasing diagnosis of opioid use disorder and uptake of OUD treatment globally.

In spite of this growth trajectory, challenges still remain such as poor insurance reimbursement, shortages in the addiction treatment workforce, regulatory issues, limitations with safety-monitoring and care coordination, stigma, and fragmented health care systems meaning patients cannot access high-quality care.

Nevertheless, opportunities also exist at the intersection of developing digital health innovations and the demand for patient-centered therapies for use in or around their homes. Investment in infrastructure around health care services, technology-based care models, and more collaborative care across sectors will help to sustain growth and create new opportunities in the OUD market.

"Impact of Global Tariff Policies on the Global Opioid Use Disorder (OUD) Market Growth and Strategy"

International tariffs create a negative impact on the OUD market by increasing the price of critical medication, digital health devices, and treatment technology used in OUD. Tariffs on pharmaceuticals, or remote monitoring equipment, coming from places like China or Mexico will increase the price of medications and supplies, and may limit patients' access to necessary treatments for their OUD.

Owing to which the supply chain issues, manufacturers are increasing the diversification of their sourcing of supplies as a way to reduce dependence on a foreign supplier, and they are investing in U.S. production capabilities. Manufacturers are also adopting more innovative technologies and utilizing more efficient processes to continue controlling costs. Policymakers will need to consider the implications of tariff policy on affordability and accessibility of OUD treatments to provide equitable care for patients.

Expansion of Global Opioid Use Disorder (OUD) Market

“Rising Addiction Rates, Digital Health Innovations, and Expanding Telemedicine Drive Opioid Use Disorder (OUD) Market Expansion”

  • The opioid use disorder (OUD) market is expanding at a significant rate spurred by increasing addiction rates around the world. More people misusing and overdosing on opioids have increased the demand for treatment options within healthcare systems. Additionally, the development of digital health innovations, such as AI-driven monitoring and telehealth platforms, is transforming the treatment of OUD, helping to achieve personalized care and continued patient engagement strategies that will improve treatment outcomes and access to care.
  • Likewise, growth in telemedicine services has made OUD treatment more accessible in rural and underserved areas, allowing for early intervention and ongoing management of OUD; reducing barriers to access and care.

Regional Analysis of Global Opioid Use Disorder (OUD) Market

  • North America dominates the opioid use disorder (OUD) space with sophisticated healthcare systems, comprehensive regulations, and readily adopting digital therapeutic tools. In February 2025, Indivior plc announced a partnership with a telehealth provider in the U.S. to increase access to long-acting injectables through virtual means, promoting adherence to care.
  • The Asia Pacific region is rapidly emerging with increasing opioid misuse, higher oncology spending, and access to treatment options. For example, the Ministry of Health in Japan launched a pilot program in 2025 that utilized AI in a mobile app to prevent relapse from substance use disorder- a fast-moving landscape in terms of digital support being utilized in opioid and addictions care.
  • Further, Europe maintains a steady pace, supported by strong public health frameworks and innovation in how care is delivered. In late 2024, the UK’s NHS launched new digital prescription tools combined with the MAT service to help serve a new approach to care coordination in the region, working to improve care and reduce relapse rates.

Key players in the global opioid use disorder (OUD) market include prominent companies such as AbbVie Inc., Alkermes PLC, Amneal Pharmaceuticals, Aurobindo Pharma, BioDelivery Sciences International, Braeburn Pharmaceuticals (Camurus AB), Cipla Limited, Dr. Reddy's Laboratories, Hikma Pharmaceuticals, Indivior PLC, Johnson & Johnson, Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals, Mylan N.V. (Viatris), Orexo AB, Par Pharmaceutical (Endo International), Pfizer Inc., Purdue Pharma, Rhodes Pharmaceuticals, Sandoz (Novartis), Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Titan Pharmaceuticals, Zydus Cadila (Cadila Healthcare), along with several other key players.

The global opioid use disorder (OUD) market has been segmented as follows:

Global Opioid Use Disorder (OUD) Market Analysis, by Treatment Type

  • Medication-Assisted Treatment (MAT)
    • Methadone
    • Buprenorphine
    • Naltrexone
    • Others
  • Behavioral Therapies
    • Cognitive Behavioral Therapy (CBT)
    • Contingency Management
    • Motivational Enhancement Therapy
    • Others
  • Combination Therapy
  • Detoxification Services

Global Opioid Use Disorder (OUD) Market Analysis, by Drug Formulation

  • Tablets
  • Sublingual Films/Tablets
  • Injectable Solutions
  • Implants
  • Extended-Release Formulations
  • Transdermal Patches
  • Others

Global Opioid Use Disorder (OUD) Market Analysis, by Route of Administration

  • Oral
  • Sublingual
  • Subcutaneous
  • Intramuscular
  • Intravenous
  • Transdermal
  • Others

Global Opioid Use Disorder (OUD) Market Analysis, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics
  • Opioid Treatment Programs (OTPs)

Global Opioid Use Disorder (OUD) Market Analysis, by Treatment Setting

  • Inpatient Treatment Facilities
    • Hospital-based Programs
    • Residential Treatment Centers
  • Outpatient Treatment Facilities
    • Ambulatory Care Centers
    • Community Health Centers
  • Home-based Treatment
  • Telemedicine/Virtual Care

Global Opioid Use Disorder (OUD) Market Analysis, by Patient Demographics

  • Age Group
    • Adolescents (12-17 years)
    • Young Adults (18-25 years)
    • Adults (26-64 years)
    • Geriatric (65+ years)
  • Gender
    • Male
    • Female

Global Opioid Use Disorder (OUD) Market Analysis, by Disease Severity

  • Mild OUD
  • Moderate OUD
  • Severe OUD
  • Relapse Cases

Global Opioid Use Disorder (OUD) Market Analysis, by Therapy Duration

  • Short-term Treatment (<3 months)
  • Medium-term Treatment (3-12 months)
  • Long-term Treatment (>12 months)

Global Opioid Use Disorder (OUD) Market Analysis, by End-Users

  • Hospitals & Clinics
    • Emergency Department Treatment
    • Inpatient Detoxification
    • Outpatient MAT Programs
    • Pain Management Transition
    • Others
  • Specialty Treatment Centers
    • Addiction Treatment Centers
    • Rehabilitation Facilities
    • Methadone Clinics
    • Buprenorphine Treatment Centers
    • Others
  • Primary Care Settings
    • General Practice MAT
    • Preventive Care
    • Screening & Assessment
    • Others
  • Mental Health Facilities
    • Dual Diagnosis Treatment
    • Psychiatric Care Integration
    • Behavioral Health Services
    • Co-occurring Disorder Treatment
    • Others
  • Correctional Facilities
    • Prison-based MAT Programs
    • Re-entry Programs
    • Detention Center Treatment
    • Parole/Probation Support
    • Others
  • Home Healthcare
    • Home-based MAT
    • Telemedicine Consultations
    • Remote Monitoring
    • Family Support Programs
    • Others
  • Community Organizations
    • Non-profit Treatment Centers
    • Peer Support Programs
    • Outreach Services
    • Others

Global Opioid Use Disorder (OUD) Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact US

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Opioid Use Disorder (OUD) Market Outlook
      • 2.1.1. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Opioid Use Disorder (OUD) Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Source Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Increasing Access to Medication-Assisted Treatment (MAT) Driving Market Growth
      • 4.1.2. Restraints
        • 4.1.2.1. Stigma and Limited Reimbursement Slowing Market Penetration
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
      • 4.4.1. Raw Material Sourcing
      • 4.4.2. Manufacturing and Processing
      • 4.4.3. Wholesalers/ E-commerce Platform
      • 4.4.4. End-use/ Customers
    • 4.5. Cost Structure Analysis
      • 4.5.1. Parameter’s Share for Cost Associated
      • 4.5.2. COGP vs COGS
      • 4.5.3. Profit Margin Analysis
    • 4.6. Pricing Analysis
      • 4.6.1. Regional Pricing Analysis
      • 4.6.2. Segmental Pricing Trends
      • 4.6.3. Factors Influencing Pricing
    • 4.7. Porter’s Five Forces Analysis
    • 4.8. PESTEL Analysis
    • 4.9. Global Opioid Use Disorder (OUD) Market Demand
      • 4.9.1. Historical Market Size – (Value - USD Bn), 2021-2024
      • 4.9.2. Current and Future Market Size – (Value - USD Bn), 2025–2035
        • 4.9.2.1. Y-o-Y Growth Trends
        • 4.9.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Opioid Use Disorder (OUD) Market Analysis, by Treatment Type
    • 6.1. Key Segment Analysis
    • 6.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Treatment Type, 2021-2035
      • 6.2.1. Medication-Assisted Treatment (MAT)
        • 6.2.1.1. Methadone
        • 6.2.1.2. Buprenorphine
        • 6.2.1.3. Naltrexone
        • 6.2.1.4. Others
      • 6.2.2. Behavioral Therapies
        • 6.2.2.1. Cognitive Behavioral Therapy (CBT)
        • 6.2.2.2. Contingency Management
        • 6.2.2.3. Motivational Enhancement Therapy
        • 6.2.2.4. Others
      • 6.2.3. Combination Therapy
      • 6.2.4. Detoxification Services
  • 7. Global Opioid Use Disorder (OUD) Market Analysis, by Drug Formulation
    • 7.1. Key Segment Analysis
    • 7.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Drug Formulation, 2021-2035
      • 7.2.1. Tablets
      • 7.2.2. Sublingual Films/Tablets
      • 7.2.3. Injectable Solutions
      • 7.2.4. Implants
      • 7.2.5. Extended-Release Formulations
      • 7.2.6. Transdermal Patches
      • 7.2.7. Others
  • 8. Global Opioid Use Disorder (OUD) Market Analysis, by Route of Administration
    • 8.1. Key Segment Analysis
    • 8.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
      • 8.2.1. Oral
      • 8.2.2. Sublingual
      • 8.2.3. Subcutaneous
      • 8.2.4. Intramuscular
      • 8.2.5. Intravenous
      • 8.2.6. Transdermal
      • 8.2.7. Others
  • 9. Global Opioid Use Disorder (OUD) Market Analysis, by Distribution Channel
    • 9.1. Key Segment Analysis
    • 9.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Distribution Channel, 2021-2035
      • 9.2.1. Hospital Pharmacies
      • 9.2.2. Retail Pharmacies
      • 9.2.3. Online Pharmacies
      • 9.2.4. Specialty Clinics
      • 9.2.5. Opioid Treatment Programs (OTPs)
  • 10. Global Opioid Use Disorder (OUD) Market Analysis, by Treatment Setting
    • 10.1. Key Segment Analysis
    • 10.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Treatment Setting, 2021-2035
      • 10.2.1. Inpatient Treatment Facilities
        • 10.2.1.1. Hospital-based Programs
        • 10.2.1.2. Residential Treatment Centers
      • 10.2.2. Outpatient Treatment Facilities
        • 10.2.2.1. Ambulatory Care Centers
        • 10.2.2.2. Community Health Centers
      • 10.2.3. Home-based Treatment
      • 10.2.4. Telemedicine/Virtual Care
  • 11. Global Opioid Use Disorder (OUD) Market Analysis, by Patient Demographics
    • 11.1. Key Segment Analysis
    • 11.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Patient Demographics, 2021-2035
      • 11.2.1. Age Group
        • 11.2.1.1. Adolescents (12-17 years)
        • 11.2.1.2. Young Adults (18-25 years)
        • 11.2.1.3. Adults (26-64 years)
        • 11.2.1.4. Geriatric (65+ years)
      • 11.2.2. Gender
        • 11.2.2.1. Male
        • 11.2.2.2. Female
  • 12. Global Opioid Use Disorder (OUD) Market Analysis, by Disease Severity
    • 12.1. Key Segment Analysis
    • 12.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Disease Severity, 2021-2035
      • 12.2.1. Mild OUD
      • 12.2.2. Moderate OUD
      • 12.2.3. Severe OUD
      • 12.2.4. Relapse Cases
  • 13. Global Opioid Use Disorder (OUD) Market Analysis, by Therapy Duration
    • 13.1. Key Segment Analysis
    • 13.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Therapy Duration, 2021-2035
      • 13.2.1. Short-term Treatment (<3 months)
      • 13.2.2. Medium-term Treatment (3-12 months)
      • 13.2.3. Long-term Treatment (>12 months)
  • 14. Global Opioid Use Disorder (OUD) Market Analysis, by End-Users
    • 14.1. Key Segment Analysis
    • 14.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by End-Users, 2021-2035
      • 14.2.1. Hospitals & Clinics
        • 14.2.1.1. Emergency Department Treatment
        • 14.2.1.2. Inpatient Detoxification
        • 14.2.1.3. Outpatient MAT Programs
        • 14.2.1.4. Pain Management Transition
        • 14.2.1.5. Others
      • 14.2.2. Specialty Treatment Centers
        • 14.2.2.1. Addiction Treatment Centers
        • 14.2.2.2. Rehabilitation Facilities
        • 14.2.2.3. Methadone Clinics
        • 14.2.2.4. Buprenorphine Treatment Centers
        • 14.2.2.5. Others
      • 14.2.3. Primary Care Settings
        • 14.2.3.1. General Practice MAT
        • 14.2.3.2. Preventive Care
        • 14.2.3.3. Screening & Assessment
        • 14.2.3.4. Others
      • 14.2.4. Mental Health Facilities
        • 14.2.4.1. Dual Diagnosis Treatment
        • 14.2.4.2. Psychiatric Care Integration
        • 14.2.4.3. Behavioral Health Services
        • 14.2.4.4. Co-occurring Disorder Treatment
        • 14.2.4.5. Others
      • 14.2.5. Correctional Facilities
        • 14.2.5.1. Prison-based MAT Programs
        • 14.2.5.2. Re-entry Programs
        • 14.2.5.3. Detention Center Treatment
        • 14.2.5.4. Parole/Probation Support
        • 14.2.5.5. Others
      • 14.2.6. Home Healthcare
        • 14.2.6.1. Home-based MAT
        • 14.2.6.2. Telemedicine Consultations
        • 14.2.6.3. Remote Monitoring
        • 14.2.6.4. Family Support Programs
        • 14.2.6.5. Others
      • 14.2.7. Community Organizations
        • 14.2.7.1. Non-profit Treatment Centers
        • 14.2.7.2. Peer Support Programs
        • 14.2.7.3. Outreach Services
        • 14.2.7.4. Others
  • 15. Global Opioid Use Disorder (OUD) Market Analysis and Forecasts, by Region
    • 15.1. Key Findings
    • 15.2. Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 15.2.1. North America
      • 15.2.2. Europe
      • 15.2.3. Asia Pacific
      • 15.2.4. Middle East
      • 15.2.5. Africa
      • 15.2.6. South America
  • 16. North America Global Opioid Use Disorder (OUD) Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. North America Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Treatment Type
      • 16.3.2. Drug Formulation
      • 16.3.3. Route of Administration
      • 16.3.4. Distribution Channel
      • 16.3.5. Treatment Setting
      • 16.3.6. Patient Demographics
      • 16.3.7. Disease Severity
      • 16.3.8. Therapy Duration
      • 16.3.9. End-Users
      • 16.3.10. Country
        • 16.3.10.1. USA
        • 16.3.10.2. Canada
        • 16.3.10.3. Mexico
    • 16.4. USA Global Opioid Use Disorder (OUD) Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Treatment Type
      • 16.4.3. Drug Formulation
      • 16.4.4. Route of Administration
      • 16.4.5. Distribution Channel
      • 16.4.6. Treatment Setting
      • 16.4.7. Patient Demographics
      • 16.4.8. Disease Severity
      • 16.4.9. Therapy Duration
      • 16.4.10. End-Users
    • 16.5. Canada Global Opioid Use Disorder (OUD) Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Treatment Type
      • 16.5.3. Drug Formulation
      • 16.5.4. Route of Administration
      • 16.5.5. Distribution Channel
      • 16.5.6. Treatment Setting
      • 16.5.7. Patient Demographics
      • 16.5.8. Disease Severity
      • 16.5.9. Therapy Duration
      • 16.5.10. End-Users
    • 16.6. Mexico Global Opioid Use Disorder (OUD) Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Treatment Type
      • 16.6.3. Drug Formulation
      • 16.6.4. Route of Administration
      • 16.6.5. Distribution Channel
      • 16.6.6. Treatment Setting
      • 16.6.7. Patient Demographics
      • 16.6.8. Disease Severity
      • 16.6.9. Therapy Duration
      • 16.6.10. End-Users
  • 17. Europe Global Opioid Use Disorder (OUD) Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Europe Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Treatment Type
      • 17.3.2. Drug Formulation
      • 17.3.3. Route of Administration
      • 17.3.4. Distribution Channel
      • 17.3.5. Treatment Setting
      • 17.3.6. Patient Demographics
      • 17.3.7. Disease Severity
      • 17.3.8. Therapy Duration
      • 17.3.9. End-Users
      • 17.3.10. Country
        • 17.3.10.1. Germany
        • 17.3.10.2. United Kingdom
        • 17.3.10.3. France
        • 17.3.10.4. Italy
        • 17.3.10.5. Spain
        • 17.3.10.6. Netherlands
        • 17.3.10.7. Nordic Countries
        • 17.3.10.8. Poland
        • 17.3.10.9. Russia & CIS
        • 17.3.10.10. Rest of Europe
    • 17.4. Germany Global Opioid Use Disorder (OUD) Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Treatment Type
      • 17.4.3. Drug Formulation
      • 17.4.4. Route of Administration
      • 17.4.5. Distribution Channel
      • 17.4.6. Treatment Setting
      • 17.4.7. Patient Demographics
      • 17.4.8. Disease Severity
      • 17.4.9. Therapy Duration
      • 17.4.10. End-Users
    • 17.5. United Kingdom Global Opioid Use Disorder (OUD) Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Treatment Type
      • 17.5.3. Drug Formulation
      • 17.5.4. Route of Administration
      • 17.5.5. Distribution Channel
      • 17.5.6. Treatment Setting
      • 17.5.7. Patient Demographics
      • 17.5.8. Disease Severity
      • 17.5.9. Therapy Duration
      • 17.5.10. End-Users
    • 17.6. France Global Opioid Use Disorder (OUD) Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Treatment Type
      • 17.6.3. Drug Formulation
      • 17.6.4. Route of Administration
      • 17.6.5. Distribution Channel
      • 17.6.6. Treatment Setting
      • 17.6.7. Patient Demographics
      • 17.6.8. Disease Severity
      • 17.6.9. Therapy Duration
      • 17.6.10. End-Users
    • 17.7. Italy Global Opioid Use Disorder (OUD) Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Treatment Type
      • 17.7.3. Drug Formulation
      • 17.7.4. Route of Administration
      • 17.7.5. Distribution Channel
      • 17.7.6. Treatment Setting
      • 17.7.7. Patient Demographics
      • 17.7.8. Disease Severity
      • 17.7.9. Therapy Duration
      • 17.7.10. End-Users
    • 17.8. Spain Global Opioid Use Disorder (OUD) Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Treatment Type
      • 17.8.3. Drug Formulation
      • 17.8.4. Route of Administration
      • 17.8.5. Distribution Channel
      • 17.8.6. Treatment Setting
      • 17.8.7. Patient Demographics
      • 17.8.8. Disease Severity
      • 17.8.9. Therapy Duration
      • 17.8.10. End-Users
    • 17.9. Netherlands Global Opioid Use Disorder (OUD) Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Treatment Type
      • 17.9.3. Drug Formulation
      • 17.9.4. Route of Administration
      • 17.9.5. Distribution Channel
      • 17.9.6. Treatment Setting
      • 17.9.7. Patient Demographics
      • 17.9.8. Disease Severity
      • 17.9.9. Therapy Duration
      • 17.9.10. End-Users
    • 17.10. Nordic Countries Global Opioid Use Disorder (OUD) Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Treatment Type
      • 17.10.3. Drug Formulation
      • 17.10.4. Route of Administration
      • 17.10.5. Distribution Channel
      • 17.10.6. Treatment Setting
      • 17.10.7. Patient Demographics
      • 17.10.8. Disease Severity
      • 17.10.9. Therapy Duration
      • 17.10.10. End-Users
    • 17.11. Poland Global Opioid Use Disorder (OUD) Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Treatment Type
      • 17.11.3. Drug Formulation
      • 17.11.4. Route of Administration
      • 17.11.5. Distribution Channel
      • 17.11.6. Treatment Setting
      • 17.11.7. Patient Demographics
      • 17.11.8. Disease Severity
      • 17.11.9. Therapy Duration
      • 17.11.10. End-Users
    • 17.12. Russia & CIS Global Opioid Use Disorder (OUD) Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Treatment Type
      • 17.12.3. Drug Formulation
      • 17.12.4. Route of Administration
      • 17.12.5. Distribution Channel
      • 17.12.6. Treatment Setting
      • 17.12.7. Patient Demographics
      • 17.12.8. Disease Severity
      • 17.12.9. Therapy Duration
      • 17.12.10. End-Users
    • 17.13. Rest of Europe Global Opioid Use Disorder (OUD) Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Treatment Type
      • 17.13.3. Drug Formulation
      • 17.13.4. Route of Administration
      • 17.13.5. Distribution Channel
      • 17.13.6. Treatment Setting
      • 17.13.7. Patient Demographics
      • 17.13.8. Disease Severity
      • 17.13.9. Therapy Duration
      • 17.13.10. End-Users
  • 18. Asia Pacific Global Opioid Use Disorder (OUD) Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. East Asia Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Treatment Type
      • 18.3.2. Drug Formulation
      • 18.3.3. Route of Administration
      • 18.3.4. Distribution Channel
      • 18.3.5. Treatment Setting
      • 18.3.6. Patient Demographics
      • 18.3.7. Disease Severity
      • 18.3.8. Therapy Duration
      • 18.3.9. End-Users
      • 18.3.10. Country
        • 18.3.10.1. China
        • 18.3.10.2. India
        • 18.3.10.3. Japan
        • 18.3.10.4. South Korea
        • 18.3.10.5. Australia and New Zealand
        • 18.3.10.6. Indonesia
        • 18.3.10.7. Malaysia
        • 18.3.10.8. Thailand
        • 18.3.10.9. Vietnam
        • 18.3.10.10. Rest of Asia-Pacific
    • 18.4. China Global Opioid Use Disorder (OUD) Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Treatment Type
      • 18.4.3. Drug Formulation
      • 18.4.4. Route of Administration
      • 18.4.5. Distribution Channel
      • 18.4.6. Treatment Setting
      • 18.4.7. Patient Demographics
      • 18.4.8. Disease Severity
      • 18.4.9. Therapy Duration
      • 18.4.10. End-Users
    • 18.5. India Global Opioid Use Disorder (OUD) Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Treatment Type
      • 18.5.3. Drug Formulation
      • 18.5.4. Route of Administration
      • 18.5.5. Distribution Channel
      • 18.5.6. Treatment Setting
      • 18.5.7. Patient Demographics
      • 18.5.8. Disease Severity
      • 18.5.9. Therapy Duration
      • 18.5.10. End-Users
    • 18.6. Japan Global Opioid Use Disorder (OUD) Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Treatment Type
      • 18.6.3. Drug Formulation
      • 18.6.4. Route of Administration
      • 18.6.5. Distribution Channel
      • 18.6.6. Treatment Setting
      • 18.6.7. Patient Demographics
      • 18.6.8. Disease Severity
      • 18.6.9. Therapy Duration
      • 18.6.10. End-Users
    • 18.7. South Korea Global Opioid Use Disorder (OUD) Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Treatment Type
      • 18.7.3. Drug Formulation
      • 18.7.4. Route of Administration
      • 18.7.5. Distribution Channel
      • 18.7.6. Treatment Setting
      • 18.7.7. Patient Demographics
      • 18.7.8. Disease Severity
      • 18.7.9. Therapy Duration
      • 18.7.10. End-Users
    • 18.8. Australia and New Zealand Global Opioid Use Disorder (OUD) Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Treatment Type
      • 18.8.3. Drug Formulation
      • 18.8.4. Route of Administration
      • 18.8.5. Distribution Channel
      • 18.8.6. Treatment Setting
      • 18.8.7. Patient Demographics
      • 18.8.8. Disease Severity
      • 18.8.9. Therapy Duration
      • 18.8.10. End-Users
    • 18.9. Indonesia Global Opioid Use Disorder (OUD) Market
      • 18.9.1. Country Segmental Analysis
      • 18.9.2. Treatment Type
      • 18.9.3. Drug Formulation
      • 18.9.4. Route of Administration
      • 18.9.5. Distribution Channel
      • 18.9.6. Treatment Setting
      • 18.9.7. Patient Demographics
      • 18.9.8. Disease Severity
      • 18.9.9. Therapy Duration
      • 18.9.10. End-Users
    • 18.10. Malaysia Global Opioid Use Disorder (OUD) Market
      • 18.10.1. Country Segmental Analysis
      • 18.10.2. Treatment Type
      • 18.10.3. Drug Formulation
      • 18.10.4. Route of Administration
      • 18.10.5. Distribution Channel
      • 18.10.6. Treatment Setting
      • 18.10.7. Patient Demographics
      • 18.10.8. Disease Severity
      • 18.10.9. Therapy Duration
      • 18.10.10. End-Users
    • 18.11. Thailand Global Opioid Use Disorder (OUD) Market
      • 18.11.1. Country Segmental Analysis
      • 18.11.2. Treatment Type
      • 18.11.3. Drug Formulation
      • 18.11.4. Route of Administration
      • 18.11.5. Distribution Channel
      • 18.11.6. Treatment Setting
      • 18.11.7. Patient Demographics
      • 18.11.8. Disease Severity
      • 18.11.9. Therapy Duration
      • 18.11.10. End-Users
    • 18.12. Vietnam Global Opioid Use Disorder (OUD) Market
      • 18.12.1. Country Segmental Analysis
      • 18.12.2. Treatment Type
      • 18.12.3. Drug Formulation
      • 18.12.4. Route of Administration
      • 18.12.5. Distribution Channel
      • 18.12.6. Treatment Setting
      • 18.12.7. Patient Demographics
      • 18.12.8. Disease Severity
      • 18.12.9. Therapy Duration
      • 18.12.10. End-Users
    • 18.13. Rest of Asia Pacific Global Opioid Use Disorder (OUD) Market
      • 18.13.1. Country Segmental Analysis
      • 18.13.2. Treatment Type
      • 18.13.3. Drug Formulation
      • 18.13.4. Route of Administration
      • 18.13.5. Distribution Channel
      • 18.13.6. Treatment Setting
      • 18.13.7. Patient Demographics
      • 18.13.8. Disease Severity
      • 18.13.9. Therapy Duration
      • 18.13.10. End-Users
  • 19. Middle East Global Opioid Use Disorder (OUD) Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Middle East Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Treatment Type
      • 19.3.2. Drug Formulation
      • 19.3.3. Route of Administration
      • 19.3.4. Distribution Channel
      • 19.3.5. Treatment Setting
      • 19.3.6. Patient Demographics
      • 19.3.7. Disease Severity
      • 19.3.8. Therapy Duration
      • 19.3.9. End-Users
      • 19.3.10. Country
        • 19.3.10.1. Turkey
        • 19.3.10.2. UAE
        • 19.3.10.3. Saudi Arabia
        • 19.3.10.4. Israel
        • 19.3.10.5. Rest of Middle East
    • 19.4. Turkey Global Opioid Use Disorder (OUD) Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Treatment Type
      • 19.4.3. Drug Formulation
      • 19.4.4. Route of Administration
      • 19.4.5. Distribution Channel
      • 19.4.6. Treatment Setting
      • 19.4.7. Patient Demographics
      • 19.4.8. Disease Severity
      • 19.4.9. Therapy Duration
      • 19.4.10. End-Users
    • 19.5. UAE Global Opioid Use Disorder (OUD) Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Treatment Type
      • 19.5.3. Drug Formulation
      • 19.5.4. Route of Administration
      • 19.5.5. Distribution Channel
      • 19.5.6. Treatment Setting
      • 19.5.7. Patient Demographics
      • 19.5.8. Disease Severity
      • 19.5.9. Therapy Duration
      • 19.5.10. End-Users
    • 19.6. Saudi Arabia Global Opioid Use Disorder (OUD) Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Treatment Type
      • 19.6.3. Drug Formulation
      • 19.6.4. Route of Administration
      • 19.6.5. Distribution Channel
      • 19.6.6. Treatment Setting
      • 19.6.7. Patient Demographics
      • 19.6.8. Disease Severity
      • 19.6.9. Therapy Duration
      • 19.6.10. End-Users
    • 19.7. Israel Global Opioid Use Disorder (OUD) Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Treatment Type
      • 19.7.3. Drug Formulation
      • 19.7.4. Route of Administration
      • 19.7.5. Distribution Channel
      • 19.7.6. Treatment Setting
      • 19.7.7. Patient Demographics
      • 19.7.8. Disease Severity
      • 19.7.9. Therapy Duration
      • 19.7.10. End-Users
    • 19.8. Rest of Middle East Global Opioid Use Disorder (OUD) Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Treatment Type
      • 19.8.3. Drug Formulation
      • 19.8.4. Route of Administration
      • 19.8.5. Distribution Channel
      • 19.8.6. Treatment Setting
      • 19.8.7. Patient Demographics
      • 19.8.8. Disease Severity
      • 19.8.9. Therapy Duration
      • 19.8.10. End-Users
  • 20. Africa Global Opioid Use Disorder (OUD) Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. Africa Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Treatment Type
      • 20.3.2. Drug Formulation
      • 20.3.3. Route of Administration
      • 20.3.4. Distribution Channel
      • 20.3.5. Treatment Setting
      • 20.3.6. Patient Demographics
      • 20.3.7. Disease Severity
      • 20.3.8. Therapy Duration
      • 20.3.9. End-Users
      • 20.3.10. Country
        • 20.3.10.1. South Africa
        • 20.3.10.2. Egypt
        • 20.3.10.3. Nigeria
        • 20.3.10.4. Algeria
        • 20.3.10.5. Rest of Africa
    • 20.4. South Africa Global Opioid Use Disorder (OUD) Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Treatment Type
      • 20.4.3. Drug Formulation
      • 20.4.4. Route of Administration
      • 20.4.5. Distribution Channel
      • 20.4.6. Treatment Setting
      • 20.4.7. Patient Demographics
      • 20.4.8. Disease Severity
      • 20.4.9. Therapy Duration
      • 20.4.10. End-Users
    • 20.5. Egypt Global Opioid Use Disorder (OUD) Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Treatment Type
      • 20.5.3. Drug Formulation
      • 20.5.4. Route of Administration
      • 20.5.5. Distribution Channel
      • 20.5.6. Treatment Setting
      • 20.5.7. Patient Demographics
      • 20.5.8. Disease Severity
      • 20.5.9. Therapy Duration
      • 20.5.10. End-Users
    • 20.6. Nigeria Global Opioid Use Disorder (OUD) Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Treatment Type
      • 20.6.3. Drug Formulation
      • 20.6.4. Route of Administration
      • 20.6.5. Distribution Channel
      • 20.6.6. Treatment Setting
      • 20.6.7. Patient Demographics
      • 20.6.8. Disease Severity
      • 20.6.9. Therapy Duration
      • 20.6.10. End-Users
    • 20.7. Algeria Global Opioid Use Disorder (OUD) Market
      • 20.7.1. Country Segmental Analysis
      • 20.7.2. Treatment Type
      • 20.7.3. Drug Formulation
      • 20.7.4. Route of Administration
      • 20.7.5. Distribution Channel
      • 20.7.6. Treatment Setting
      • 20.7.7. Patient Demographics
      • 20.7.8. Disease Severity
      • 20.7.9. Therapy Duration
      • 20.7.10. End-Users
    • 20.8. Rest of Africa Global Opioid Use Disorder (OUD) Market
      • 20.8.1. Country Segmental Analysis
      • 20.8.2. Treatment Type
      • 20.8.3. Drug Formulation
      • 20.8.4. Route of Administration
      • 20.8.5. Distribution Channel
      • 20.8.6. Treatment Setting
      • 20.8.7. Patient Demographics
      • 20.8.8. Disease Severity
      • 20.8.9. Therapy Duration
      • 20.8.10. End-Users
  • 21. South America Global Opioid Use Disorder (OUD) Market Analysis
    • 21.1. Key Segment Analysis
    • 21.2. Regional Snapshot
    • 21.3. Central and South Africa Global Opioid Use Disorder (OUD) Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
      • 21.3.1. Treatment Type
      • 21.3.2. Drug Formulation
      • 21.3.3. Route of Administration
      • 21.3.4. Distribution Channel
      • 21.3.5. Treatment Setting
      • 21.3.6. Patient Demographics
      • 21.3.7. Disease Severity
      • 21.3.8. Therapy Duration
      • 21.3.9. End-Users
      • 21.3.10. Country
        • 21.3.10.1. Brazil
        • 21.3.10.2. Argentina
        • 21.3.10.3. Rest of South America
    • 21.4. Brazil Global Opioid Use Disorder (OUD) Market
      • 21.4.1. Country Segmental Analysis
      • 21.4.2. Treatment Type
      • 21.4.3. Drug Formulation
      • 21.4.4. Route of Administration
      • 21.4.5. Distribution Channel
      • 21.4.6. Treatment Setting
      • 21.4.7. Patient Demographics
      • 21.4.8. Disease Severity
      • 21.4.9. Therapy Duration
      • 21.4.10. End-Users
    • 21.5. Argentina Global Opioid Use Disorder (OUD) Market
      • 21.5.1. Country Segmental Analysis
      • 21.5.2. Treatment Type
      • 21.5.3. Drug Formulation
      • 21.5.4. Route of Administration
      • 21.5.5. Distribution Channel
      • 21.5.6. Treatment Setting
      • 21.5.7. Patient Demographics
      • 21.5.8. Disease Severity
      • 21.5.9. Therapy Duration
      • 21.5.10. End-Users
    • 21.6. Rest of South America Global Opioid Use Disorder (OUD) Market
      • 21.6.1. Country Segmental Analysis
      • 21.6.2. Treatment Type
      • 21.6.3. Drug Formulation
      • 21.6.4. Route of Administration
      • 21.6.5. Distribution Channel
      • 21.6.6. Treatment Setting
      • 21.6.7. Patient Demographics
      • 21.6.8. Disease Severity
      • 21.6.9. Therapy Duration
      • 21.6.10. End-Users
  • 22. Key Players/ Company Profile
    • 22.1. AbbVie Inc.
      • 22.1.1. Company Details/ Overview
      • 22.1.2. Company Financials
      • 22.1.3. Key Customers and Competitors
      • 22.1.4. Business/ Industry Portfolio
      • 22.1.5. Product Portfolio/ Specification Details
      • 22.1.6. Pricing Data
      • 22.1.7. Strategic Overview
      • 22.1.8. Recent Developments
    • 22.2. Alkermes PLC
    • 22.3. Amneal Pharmaceuticals
    • 22.4. Aurobindo Pharma
    • 22.5. BioDelivery Sciences International
    • 22.6. Braeburn Pharmaceuticals (Camurus AB)
    • 22.7. Cipla Limited
    • 22.8. Dr. Reddy's Laboratories
    • 22.9. Hikma Pharmaceuticals
    • 22.10. Indivior PLC
    • 22.11. Johnson & Johnson
    • 22.12. Lupin Pharmaceuticals
    • 22.13. Mallinckrodt Pharmaceuticals
    • 22.14. Mylan N.V. (Viatris)
    • 22.15. Orexo AB
    • 22.16. Par Pharmaceutical (Endo International)
    • 22.17. Pfizer Inc.
    • 22.18. Purdue Pharma
    • 22.19. Rhodes Pharmaceuticals
    • 22.20. Sandoz (Novartis)
    • 22.21. Sun Pharmaceutical Industries
    • 22.22. Teva Pharmaceutical Industries
    • 22.23. Titan Pharmaceuticals
    • 22.24. Zydus Cadila (Cadila Healthcare)
    • 22.25. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation